Autism and metabolic diseases – more treatable ‘autisms’ hiding in plain sight?

Sep 10, 2021Autism Science and Research News

Metabolism is the process through which our bodies convert nutrients from food and drink into energy. We need energy for the basics of life, such as breathing or blood circulation, and so countless metabolic processes take place in our cells and our organs all the time, even while we rest and sleep.

What are inborn errors of metabolism?

Inborn errors of metabolism (IEM), sometimes called inherited metabolic diseases, are rare genetic disorders in which a single genetic mutation affects one or more biochemical pathways, that is, specific sequences of chemical reactions, that are involved in metabolism.

The disorders are usually caused by errors in specific enzymes that help break down parts of food. A food product that is not broken down and converted into energy can become toxic, and can build up in the body over time affecting the functioning of many organs, including the brain.

There are currently over 700 known IEMs, and new ones are being discovered constantly through technological diagnostic advances, and through more widespread use of whole genome sequencing.

The latest estimates show that IEMs occur in approximately 1 in 1000 people.

There are different types of IEMs, according to what types of metabolic process they affect, for example purine and pyrimidine disorders, lysosomal or glycogen storage disorders, organic acidemias, fatty acid oxidation disorders, urea cycle disorders, and many others.

Lots of IEMs cause severe symptoms and can often be fatal, but there are others that cause mild and/or unspecific symptoms that overlap with more common disorders.

“Non-classic or variant-type inborn errors of metabolism may be manifested at any age and may not show all or even any of the features usually associated with the classic descriptions of these disorders. The practitioner must maintain an index of suspicion in the approach to diagnosis of any of these disorders, especially when the patient is out of infancy.” (Chinsky & Steinter 2009)

Signs and symptoms of inborn errors of metabolism

Symptoms of IEMs are often present from birth or early childhood, but in some cases they can become noticeable only much later, in late childhood and even in adult life.

Possible signs in newborns/babies include:

  • neonatal seizures
  • lethargy
  • vomiting
  • abnormal breathing
  • hypotonia (underdeveloped muscle tone) or hypertonia (overdeveloped muscle tone)
  • poor feeding
  • failure to thrive
  • jaundice
  • slow development or developmental regression
  • abnormal eye movements
  • dysmorphic (abnormal) features of the face and head
  • abnormal body or urine odour
  • abnormal hair or skin texture

Some symptoms, like dysmorphic facial features, may not be obvious at birth, but they become more pronounced over time.

Later in a child’s life, or even in adolescence or adulthood, some other problems may become more prominent, such as:

  • movement and motor difficulties
  • intellectual disability
  • psychiatric symptoms (such as anxiety or aggression)
  • strokes or stroke-like episodes
  • seizures or other symptoms triggered by specific activities such as fasting or change in physical activity level.

“IEMs may rarely present with ASD symptoms. Careful evaluation of the history, physical examination and recording the additional findings in patients diagnosed with ASD will guide the clinician in the decision-making process of metabolic tests. An underlying IEM can be a treatable cause of autism. Detailed metabolic screening in a Greek cohort of ASD patients revealed biomarkers in 7% (13/187) of patients for whom biotin supplementation or institution of a ketogenic diet resulted in mild to significant clinical improvement in autistic features.”
(Spilioti 2013)

Inborn errors of metabolism in autism – overlooked symptoms and missed diagnosis?

Autism frequently occurs in some types of inborn errors of metabolism, usually alongside intellectual disability and some degree of motor impairment.

Although it is often estimated that less than 5% of autism is due to underlying metabolic disease, it is possible that some of the cases are being missed and that the true prevalence of IEM in autism could be slightly higher.

A study by Spilioti and colleagues published in 2013 examined 187 Greek children with autism for the presence of metabolic abnormalities. It was discovered that:

“Twelve patients (7%) manifested increased 3-hydroxyisovaleric acid (3-OH-IVA) excretion in urine, and minor to significant improvement in autistic features was observed in seven patients following supplementation with biotin. Five diagnoses included: Lesch Nyhan syndrome (2), succinic semialdehyde dehydrogenase (SSADH) deficiency (2), and phenylketonuria (1) (2.7%)….Six patients with elevated b-OH-b in sera showed improved autistic features following implementation of a ketogenic diet.” (Spilioti 2013)

In a recent study by İnci and colleagues the hospital records data of 247 children with autism were examined in order to investigate possible missed cases of IEM. After detailed investigation, six patients were each diagnosed with a previously undiagnosed inborn error of metabolism: phenylketonuria, cerebral creatine deficiency, hypobetalipoproteinemia, glycogen storage disease type IX-a, dihydropyrimidine dehydrogenase deficiency, and succinic semialdehyde dehydrogenase deficiency.

Cakar and Yilmazbas reported similar findings from their investigation. In a group of 179 Turkish patients with autism who presented to their clinic, and as a result of specific metabolic examinations performed, six (3.3%) patients were diagnosed with inborn errors of metabolism. Two  patients were diagnosed with classical phenylketonuria, two with classical homocystinuria, one with mucopolysaccharidosis type 3D (Sanfilippo syndrome) and one with 3-methylchrotonyl Co-A carboxylase deficiency.

Similarly, investigation by Shi and colleagues published in 2019 revealed that out of 277 Chinese children with autism, over 5% were suffering from an underlying, previously missed metabolic disorder:

“Three cases of phenylketonuria, one case of homocysteinemia, one case of propionemia, one case of methylmalonic acidemia, one case of glutaric acidemia, one case of isovaleric acidemia, one case of argininemia, one case of citrullinemia I and four cases of primary carnitine deficiency were confirmed by genetic testing, which yielded an overall diagnostic rate of 5.1% (14/277). … Our result has provided further evidence for the co-occurrence of ASD and IEM. Tandem mass spectrometry has a great value for the diagnosis and treatment of ASD in childhood.” (Shi et al. 2019)

An investigation by of a group of 50 Mexican children with autism also revealed two cases of previously undiagnosed IEMs. Three patients showed abnormal blood acylcarnitine and amino acid results. Confirmatory studies were positive in two of the patients, both of whom had organic acidemias. One of the diagnosed patients, an 11-year-old girl, began nutritional treatment which led to visible improvements in the core autism symptoms — social communication and social interaction domains.

“Currently, the patient can share a smile, has good eye contact, and understands gestures. She has interest in peers and maintains social interaction (this interaction was previously brief and inappropriate)” (Marquez‑Caraveo et al. 2020)

The authors noted however that one limitation of their study was that the screening test that was used here  

only allowed the detection of amino acid diseases, organic acidemias and fatty acid oxidation disorders. Other IEMs involving large molecules (such as lysosomal disorders) that could be the cause of neurodevelopmental symptomatology were not included, and therefore ‘the number of cases with other IEMs may be even greater.’

Phenylketonuria (PKU) is an inherited metabolic disorder in which amino acid called phenylalanine cannot be broken down by the normal metabolic processes and instead builds up in the body. High levels of phenylalanine can damage the central nervous system and cause intellectual disability, seizures, anxiety, depression and behavioural problems.

“This case illustrates that because the majority of autism cases are idiopathic, an occasional patient with a metabolic disorder might be overlooked especially in the era of newborn screening. We…wish to draw attention to the possibility of cases missed in the screening program because of less than 100% coverage or insufficient food intake before blood sampling. Clinicians should keep in mind the possibility of treatable disorders in children with autism even when such disorders appear unlikely.”
(Mazlum et al. 2016)

Although the exact prevalence rate of autism in PKU is unknown, the relationship between autism and PKU is well documented, and it is thoughts that the toxic levels of phenylalanine play a significant role in the development of autism symptomatology.

Numerous published case reports and case series studies have repeatedly revealed late diagnosis and/or untreated PKU causing autism-related symptoms. In most cases those patients would show reduction in autism symptoms and improved mental functioning after commencing a PKU-specific, low-phenylalanine diet.

“The possibility of a metabolic disorder including PKU should be considered in any child presenting with symptoms of autism, learning or speech problems and PKU should be tested unless the newborn screening results are available. Even late diagnosed patients benefit from a restricted diet, as in this case who might have had a milder form of PKU and achieved normal school performance.” (Yıldız et al. 2020)

“This case illustrates that because the majority of autism cases are idiopathic, an occasional patient with a metabolic disorder might be overlooked especially in the era of newborn screening. We also…wish to draw attention to the possibility of cases missed in the screening program because of less than 100% coverage or insufficient food intake before blood sampling. Clinicians should keep in mind the possibility of treatable disorders in children with autism even when such disorders appear unlikely.” (Mazlum et al. 2016)

In addition to PKU, another type of IEM that has been reported to be a missed cause of autism in children is creatine transporter deficiency, or brain creatine deficiency.

A case study published in 2018 reported a case of creatine transporter deficiency (CDT) in two brothers with Autism Spectrum Disorder, diagnosed when the brothers were aged 17 and 12. The authors report that both patients were given creatine monohydrate, L-arginine, L-glycine and S-adenosylmethionine upon CDT diagnosis, which partially improved their behavioral and autism-related symptoms.

“Serum creatinine levels, creatine peak at brain MR spectroscopy or creatine/creatinine ratio in urine should be evaluated to identify Creatine Transporter Deficiency in children with autistic behavior and language disorders.” (Aydin 2018)

Similarly, Yildiz et al. reported in 2020 a case of a six-year-old boy presenting to the clinic for diagnostic investigation of ASD. His brain MRI showed ‘normal pallidal intensities but a significantly decreased creatine peak’, which prompted further investigation into creatine metabolism with urine and genetic analysis confirming the diagnosis of Creatine Transporter Deficiency.

“Cerebral creatine deficiency should be included in the differential diagnosis in children with autistic symptoms, seizures, movement disorders, developmental delay, and language impairment.” (Yildiz et al. 2020)

Some of the other IEMs with frequently occurring autism symptoms include:

  • disorders of branched-chain amino acids
  • biotinidase deficiency, mitochondrial disorders (e.g. mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes—MELAS syndrome)
  • disorders of folate transport and metabolism (cerebral folate deficiency, methylenetetrahydrofolate reductase deficiency)
  • urea cycle disorders, disorders in purine metabolism (adenosine deaminase deficiency, adenylosuccinate lyase deficiency, dihydropyrimidine dehydrogenase and dihydropyrimidinase deficiencies)
  • organic acidurias (such as propionic academia, 3-methylcrotonyl-CoA carboxylase deficiency and pyridoxine dependency)
  • succinic semialdehyde dehydrogenase deficiency
  • glucose 6-phosphate dehydrogenase deficiency
  • lysosomal storage disorders (Niemann-Pick disease type C, Sanfilippo syndrome, neuronal ceroid lipofuscinoses)
  • brain iron accumulation diseases
  • disorders of copper metabolism (Wilson disease).

For a more comprehensive list see paper ‘Inborn Errors of Metabolism Associated With Autism Spectrum Disorders: Approaches to Intervention’ by Zigman et al.)

It should be noted that the IEM with the highest incidence of autism is Smith-Lemli-Opitz syndrome (SLOS), which is caused by an abnormality in cholesterol metabolism. SLOS is characterized by distinctive facial features, growth restriction, intellectual disability, small head size (microcephaly), feeding and gastrointestinal issues, and behavioral problems (irritability, sensory hyperreactivity, sleep disturbances). About half of children with SLOS also have autism. Dietary therapy and cholesterol supplementation often lead to developmental, cognitive and behavioural improvements in these children.

Testing and diagnosis

Many IEMs are tested for routinely at birth, but the precise number and types of tests, and the number of IEMs that are targeted through those tests, varies from country to country.

In the UK babies are screened at birth for only six IEMs, or inherited metabolic diseases. These are:

  • phenylketonuria (PKU)
  • medium-chain acyl-CoA dehydrogenase deficiency (MCADD)
  • maple syrup urine disease (MSUD)
  • isovaleric acidaemia (IVA)
  • glutaric aciduria type 1 (GA1) and
  • homocystinuria (pyridoxine unresponsive) (HCU)

Some, but not all, IEMs can be accompanied by structural brain anomalies and/or by specific EEG changes. Brain MRI can sometimes aid the correct diagnosis of an IEM, or it can be used to flag a possible issue and signpost towards more detailed urine/blood/genetic tests.

In the absence of, or before a full genetic screening, abnormal values in the following metabolic tests can raise suspicion of IEM:

  • Acidosis
  • Respiratory alkalosis
  • Hypoglycemia
  • Elevated or low-absent urine ketones
  • Urine reducing substances (in absence of glucosuria)
  • Hyperammonemia
  • Low blood urea nitrogen (especially with appearance of dehydration)
  • Lactic acidosis
  • Hyperuricemia
  • Low uric acid
  • Low cholesterol

Some of the available laboratory tests which can be used to identify IEMs are listed below.
(based on TIDE BC protocol and TIDE app)

BLOOD

  • Lactate
  • Ammonia
  • Folate
  • Transferrin /N-glycan profiling
  • Very long chain fatty acids
  • Plasma amino acids
  • Total homocysteine
  • Acylcarnitine profile
  • Copper, ceruloplasmin

URINE

  • Organic acids
  • Glycosaminoglycans
  • Purines & pyrimidines
  • Creatine metabolites
  • Oligosaccharides
  • Guanidinoacetate/li>

For details on second-tier tests see TIDE BC protocol and TIDE app

Exome sequencing and targeted molecular analysis
(for details see TIDE BC protocol and TIDE app
Recent advances in laboratory testing technology have facilitated much easier identification of IEMs.

“The addition of a serum ammonia level to the laboratory evaluation …will identify many children with inborn errors of metabolism.” (Denmark, 2006)

“Especially during the recent years, significant achievements have been gained for the biochemical and genetic diagnosis of inborn errors. Techniques such as tandem mass spectrometry and gas chromatography for biochemical diagnosis and microarrays and next-generation sequencing for the genetic diagnosis have enabled rapid and accurate diagnosis.” (Egzu, 2016)

If screening laboratory tests point toward a specific disease, further confirmation through genetic testing is often necessary.

Treatments

Many IEMs are treatable. Approximately 200 IEMs have a specific treatment that can prevent or reduce neurobiological damage and disability. The treatment is specific to the particular gene or a specific metabolic pathway that is affected in each case, and consists of restoration of the disrupted pathway.

The most common treatments consist of dietary modification, in other words avoiding foods that are affected by the dysfunctional metabolic pathway. One such example is PKU, which can be treated with a restricted phenylalanine diet.

In some cases the treatment consists of replacement of the missing enzyme, metabolite or cofactor (for example, creatine or biotin). Enzyme replacement therapy is now a well-established treatment for some IEMs, for example Gaucher disease. In some rare cases the treatment options will include the removal of toxic metabolite from the body, or even organ transplantation.

“Given their frequency and potential for treatment, the clinician should be aware of this group of conditions and learn to identify the typical manifestations of the different inborn errors of metabolism.” (Ferreira & van Karnebeek, 2019)

Given the high levels of co-occurrence of IEMs with autism, and the fact that autism is frequently accompanied by symptoms that could indicate presence of a metabolic disorder, such as intellectual disability, developmental regression, seizures, motor difficulties etc, it is important for clinicians to maintain a high index of suspicion for various IEMs when diagnosing a child with autism.

“Clinicians should think of metabolic testing with urine-blood aminoacid chromatography, or tandem mass spectrometry in cases with autism or learning difficulties even in the absence of intellectual disability and even in the era of newborn metabolic screening in order not to overlook treatable conditions.” (Mazlum et al. 2016)

“Clinicians are advised to maintain a high index of suspicion for IEM and to evaluate patients with ASD for syndromic features. Although current guidelines from relevant organizations differ in their recommendations regarding the necessity and the extent of metabolic screening in ASD, there is a growing trend toward screening for treatable IEM.” (Yildiz et al. 2020)

“Clues that should raise suspicion of a metabolic disorder in ASD include metabolic acidosis, recurrent vomiting, developmental regression, motor abnormalities (hypotonia, dystonia, spasticity, etc), seizures, microcephaly, failure to thrive, and involvement of other organ systems. ASD can be a feature of a variety of IEM, including disorders of creatine metabolism, untreated phenylketonuria, cerebral folate deficiency, succinic semialdehyde dehydrogenase deficiency, mucopolysaccharidosis type III, and purine and pyrimidine disorders. One should note that development risk factors such as complicated pregnancy, prematurity, or a presumed diagnosis of cerebral palsy or ASD may easily shadow IEM.”
(Yildiz et al. 2020)

Further reading and resources, including an interactive tool for a diagnosing clinician can be found on Treatable Intellectual Disability Endeavor in BC website as well as their ‘Treatable-ID’ mobile app. The Treatable-ID App was created in 2012 as digital tool to improve early recognition and intervention for treatable inherited metabolic disorders presenting with intellectual disability (‘Treatable IDs’). Click here for the website version of ‘Treatable ID’ app.

References:

Agana, M. et al. (2018) ‘Common metabolic disorder (inborn errors of metabolism) concerns in primary care practice’, Annals of Translational Medicine. AME Publications, 6(24), pp. 469–469. doi: 10.21037/ATM.2018.12.34.

Aydin HI (2018) ‘Creatine Transporter Deficiency in Two Brothers with Autism Spectrum Disorder.’, Indian Pediatr., 55(1), pp. 67–68.

Cakar, N. E. and Yilmazbas, P. (2021) ‘Cases of inborn errors of metabolism diagnosed in children with autism’, Ideggyogyaszati Szemle. Ifjusagi Lap-es Konyvkiado Vallalat, 74(1–2), pp. 67–72. doi: 10.18071/ISZ.74.0067.

Chinsky, J. M. and Steiner, R. D. (2009) ‘Inborn Errors of Metabolism’, Developmental-Behavioral Pediatrics. W.B. Saunders, pp. 287–313. doi: 10.1016/B978-1-4160-3370-7.00030-4.

Demirci , E. (2017) ‘Autism Spectrum Disorder and Phenylketonuria: Dyzygotic Twins with Double Syndrome’, Archives of Neuropsychiatry. Turkish Neuropsychiatric Society, 54(1), p. 92. doi: 10.5152/NPA.2016.12500.

Denmark, T. K. (2008) ‘Inborn Errors of Metabolism’, Pediatric Emergency Medicine. W.B. Saunders, pp. 273–276. doi: 10.1016/B978-141600087-7.50032-5.

Ebrahimi-Fakhari, D., Karnebeek, C. Van and Münchau, A. (2019) ‘Movement Disorders in Treatable Inborn Errors of Metabolism’, Movement Disorders. John Wiley & Sons, Ltd, 34(5), pp. 598–613. doi: 10.1002/MDS.27568.

Ezgu, F. (2016) ‘Inborn Errors of Metabolism’, Advances in Clinical Chemistry. Elsevier, 73, pp. 195–250. doi: 10.1016/BS.ACC.2015.12.001.

İnci, A. et al. (2021) ‘Autism: Screening of inborn errors of metabolism and unexpected results’, Autism Research. John Wiley & Sons, Ltd, 14(5), pp. 887–896. doi: 10.1002/AUR.2486.

Jones, P., Patel, K. and Rakheja, D. (2020) ‘Introduction’, A Quick Guide to Metabolic Disease Testing Interpretation. Academic Press, pp. 3–14. doi: 10.1016/B978-0-12-816926-1.00001-8.

Kiykim, E. et al. (2016) ‘Inherited metabolic disorders in Turkish patients with autism spectrum disorders’, Autism Research. John Wiley & Sons, Ltd, 9(2), pp. 217–223. doi: 10.1002/AUR.1507.

Kruszka, P. and Regier, D. (2019) ‘Inborn Errors of Metabolism: From Preconception to Adulthood’, American Family Physician, 99(1), pp. 25–32. Available at: www.aafp.org/afp (Accessed: 23 August 2021).

Leuzzi, V. et al. (2013) ‘Inborn errors of creatine metabolism and epilepsy’, Epilepsia. John Wiley & Sons, Ltd, 54(2), pp. 217–227. doi: 10.1111/EPI.12020.

Lowe, T. L. et al. (1980) ‘Detection of Phenylketonuria in Autistic and Psychotic Children’, JAMA. American Medical Association, 243(2), pp. 126–128. doi: 10.1001/JAMA.1980.03300280024022.

Ma, Y. et al. (2021) ‘Differential Metabolites in Chinese Autistic Children: A Multi-Center Study Based on Urinary 1H-NMR Metabolomics Analysis’, Frontiers in Psychiatry. Frontiers Media SA, 12, p. 624767. doi: 10.3389/FPSYT.2021.624767.

Márquez-Caraveo, M. E. et al. (2020) ‘Brief Report: Delayed Diagnosis of Treatable Inborn Errors of Metabolism in Children with Autism and Other Neurodevelopmental Disorders’, Journal of Autism and Developmental Disorders 2020 51:6. Springer, 51(6), pp. 2124–2131. doi: 10.1007/S10803-020-04682-2.

Mazlum, B. et al. (2016) ‘A late-diagnosed phenylketonuria case presenting with autism spectrum disorder in early childhood’, Turkish Journal of Pediatrics. Turkish Journal of Pediatrics, 58(3), pp. 318–322. doi: 10.24953/TURKJPED.2016.03.016.

Newmeyer, A. et al. (2008) ‘Screening of Male Patients with Autism Spectrum Disorder for Creatine Transporter Deficiency’, Neuropediatrics. © Georg Thieme Verlag KG Stuttgart · New York, 38(06), pp. 310–312. doi: 10.1055/S-2008-1065353.

Rahman, S. et al. (2013) ‘Inborn errors of metabolism causing epilepsy’, Developmental Medicine & Child Neurology. John Wiley & Sons, Ltd, 55(1), pp. 23–36. doi: 10.1111/J.1469-8749.2012.04406.X.

Saad, K. et al. (2013) ‘Autistic Symptoms in Late Diagnosed Phenylketonuric Children in Upper Egypt’, Journal of Neurology Research, 3(3–4), pp. 122–129. doi: 10.4021/JNR.V3I3-4.221.

Schulze, A. et al. (2016) ‘Prevalence of Creatine Deficiency Syndromes in Children With Nonsyndromic Autism’, Pediatrics. American Academy of Pediatrics, 137(1). doi: 10.1542/PEDS.2015-2672.

Serdari, A. E., Zompola, C. and Evangeliou, A. (2021) ‘Delayed phenylketonuria diagnosis: a challenging case in child psychiatry’, Journal of Pediatric Endocrinology and Metabolism. De Gruyter, 34(1), pp. 127–130. doi: 10.1515/JPEM-2020-0243.

Shi, H., Wang, J. and Zhao, Z. (2019) ‘[Analysis of inborn error metabolism in 277 children with autism spectrum disorders from Hainan]’, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 36(9), pp. 870–873. doi: 10.3760/CMA.J.ISSN.1003-9406.2019.09.004.

Spilioti, M. et al. (2013) ‘Evidence for treatable inborn errors of metabolism in a cohort of 187 Greek patients with autism spectrum disorder (ASD)’, Frontiers in Human Neuroscience. Frontiers Media SA, 7(DEC). doi: 10.3389/FNHUM.2013.00858.

Stockler-Ipsiroglu, S. and Karnebeek, C. D. M. van (2014) ‘Cerebral Creatine Deficiencies: A Group of Treatable Intellectual Developmental Disorders’, Seminars in Neurology. Thieme Medical Publishers, 34(03), pp. 350–356. doi: 10.1055/S-0034-1386772.

Stromberger, C., Bodamer, O. A. and Stöckler-Ipsiroglu, S. (2003) ‘Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism’, Journal of Inherited Metabolic Disease. John Wiley & Sons, Ltd, 26(2–3), pp. 299–308. doi: 10.1023/A:1024453704800.

Wijburg, F. A. et al. (2013) ‘Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder’, Acta Paediatrica (Oslo, Norway : 1992). Wiley-Blackwell, 102(5), p. 462. doi: 10.1111/APA.12169.

Wolfenden, C., Wittkowski, A. and Hare, D. J. (2017) ‘Symptoms of Autism Spectrum Disorder (ASD) in Individuals with Mucopolysaccharide Disease Type III (Sanfilippo Syndrome): A Systematic Review’, Journal of Autism and Developmental Disorders. Springer, 47(11), p. 3620. doi: 10.1007/S10803-017-3262-6.

Yıldız, Y. et al. (2020) ‘Creatine Transporter Deficiency Presenting as Autism Spectrum Disorder’, Pediatrics. American Academy of Pediatrics, 146(5). doi: 10.1542/PEDS.2019-3460.

Žigman, T. et al. (2021) ‘Inborn Errors of Metabolism Associated With Autism Spectrum Disorders: Approaches to Intervention’, Frontiers in Neuroscience. Frontiers Media SA, 15. doi: 10.3389/FNINS.2021.673600.

DISCLAIMER

The purpose of this site is to provide information. No information on this website should be construed as medical advice. Neither article authors, associated charities, nor individual contributors take any responsibility or liability for any decision taken by site visitors as a result of the information contained herein or the external links provided. If you need medical advice, please seek it from a suitably qualified practitioner.
Synchrony 2019 – Translational Research in Autism symposia

Synchrony 2019 – Translational Research in Autism symposia

The first Brain Foundation annual symposia, Pleasanton, California 8-10 of Nov 2019, aimed to connect researchers with clinicians, donors & stake holders to help translate research efforts into evidence-based treatments for autism and its co-morbidities. It highlighted the need for multidisciplinary collaboration, detailed diagnostics and personalised treatment…

Transcranial direct current stimulation tDCS – a novel treatment for autism?

Transcranial direct current stimulation tDCS – a novel treatment for autism?

One of the treatment modalities that has shown the greatest promise for reducing symptoms of autism in recent years is transcranial direct current stimulation (tDCS). The most recent study confirmed and expanded on the findings of previous investigations, which strongly indicate that tDCS could have positive effects on cognition, behaviour and physical health, and improve quality of life and autonomy for a large percentage of individuals with autism.

Century-old drug offers new hope for autism treatment

Century-old drug offers new hope for autism treatment

A small double-blind, placebo-controlled trial shows dramatic effects of suramin as a treatment for autism. Improvements were seen in all three core features of autism: language, social interactions, and restricted or repetitive behaviours across multiple diagnostics in multiple tests in all who received the active treatments, absent in the placebo arm

Keep informed - subscribe to our mailing list

We will email you autism-related news and updates. You can unsubscribe at any time.

No social media or google account? Sign up with your email address:

.
DISCLAIMER The purpose of this site is to provide information. No information on this website should be construed as medical advice. Neither article authors, associated charities, nor individual contributors take any responsibility or liability for any decision taken by site visitors as a result of the information contained herein or the external links provided. If you need medical advice, please seek it from a suitably qualified practitioner.

Privacy Policy  |  Terms and Conditions
© 2020 Thinking Autism | All rights reserved | Registered Charity: No. 1113628, Limited Company Registered in England: No. 05594787 | Registered address: International House, 24 Holborn Viaduct, London, EC1A 2BN | Contact tel. 07518131697